The efficacy of an anti-CD38 IB4/saporin-S6 was evaluated in different CD38+ human cell lines and in CD38+ malignant cells from a non-Hodgkin lymphoma (NHL) patient. Here, CD38 is linked to non-Hodgkin lymphoma.